New dosing strategy aims to tame aggressive prostate cancer with less harm
NCT ID NCT03042468
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times
Summary
This study is for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy. Researchers are testing a drug called 177Lu-PSMA-617, which delivers radiation directly to cancer cells. The goal is to find the highest dose that can be given safely by splitting it into smaller, more frequent doses. About 50 participants will be enrolled to see if this approach reduces side effects while still fighting the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tulane Cancer Center Clinic
New Orleans, Louisiana, 70112, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.